PATIENT INFORMATION LEAFLET
Eplerenona Combix 50 mg Film-Coated Tablets
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
Eplerenona Combix belongs to a group of medications known as selective aldosterone blockers. These blockers inhibit the action of aldosterone, a substance produced by the body that controls blood pressure and cardiac function. Elevated levels of aldosterone can produce changes in the body that lead to heart failure.
Eplerenona Combix is used to treat heart failure to prevent worsening and reduce hospitalization if you have
Do not take Eplerenona Combix
Warnings and precautions
Consult your doctor or pharmacist before starting to take eplerenone:
Use of Eplerenona Combix with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Eplerenone may affect other medications. These, in turn, may affect the proper functioning of eplerenone.
Do not take Eplerenona Combix with the following medications (see "Do not use Eplerenona Combix"):
Inform your doctor if you are taking any of the following medications:
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Taking Eplerenona Combix with food and drinks
Eplerenona Combix can be taken with or without food.
Pregnancy and breastfeeding
The effect of Eplerenona Combix during pregnancy in humans has not been evaluated.
It is unknown whether eplerenone is excreted in breast milk. Your doctor will decide with you whether to stop breastfeeding or suspend treatment.
If you are pregnant or breastfeeding, or if you think you may be pregnant or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
After taking Eplerenona Combix, you may feel dizzy. If this happens, do not drive or operate machinery.
Eplerenona Combix contains lactose
If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.
Follow exactly the administration instructions for Eplerenona Combix as indicated by your doctor. Consult your doctor or pharmacist again if you have any doubts.
Eplerenona Combix tablets can be taken with or without food. Swallow the tablets whole with plenty of water.
Eplerenona Combix is usually administered together with other medications for heart failure, for example, beta-blockers. The usual initial dose is one 25 mg tablet once a day, increasing after 4 weeks to 50 mg daily (one 50 mg tablet or two 25 mg tablets). The maximum dosage regimen is 50 mg per day.
Blood potassium levels should be measured before starting treatment with Eplerenona Combix, during the first week, and one month after starting treatment or after a change in dosage.
Your doctor may adjust the dose based on your blood potassium levels.
If you have mild renal insufficiency, you should start treatment with one 25 mg tablet per day, and if you have moderate renal insufficiency, you should start treatment with one 25 mg tablet every other day. These doses may be adjusted, if your doctor indicates, and according to your blood potassium levels.
Eplerenona Combix is not recommended for patients with severe renal disease.
No initial dose adjustment is required for patients with mild to moderate liver insufficiency. If you have liver or kidney problems, you may need to have your blood potassium levels checked more frequently (see also “Do not take Eplerenona Combix”).
In the elderly: no initial dose adjustment is required.
In children and adolescents: Eplerenona Combix is not recommended.
If you take more Eplerenona Combix than you should
If you take more Eplerenona Combix than you should, inform your doctor or pharmacist immediately. If you have taken too much medication, the most likely symptoms will be low blood pressure (manifested as dizziness, blurred vision, weakness, acute loss of consciousness) or hyperkalemia, high levels of potassium in the blood (manifested by muscle cramps, diarrhea, nausea, dizziness, or headache).
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Eplerenona Combix
If it is almost time to take the next tablet, skip the dose you forgot and take the next tablet at the usual time.
Otherwise, take the tablet as soon as you remember, as long as more than 12 hours have passed since the usual time to take the next tablet. Then, resume your medication as usual. Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Eplerenona Combix
It is essential to continue taking Eplerenona Combix as instructed, unless your doctor tells you to stop treatment. If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, Eplerenona Combix may have side effects, although not everyone will experience them.
If any of the following occur:
Seek immediate medical attention
These are symptoms of angioneurotic edema.
Other side effects reported include:
Frequent side effects(occur in 1 to 10 of every 100 patients):
Rare side effects(occur in 1 to 10 of every 1,000 patients):
If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this prospectus.
Keep this medication out of the sight and reach of children.
Do not use Eplerenona Combix after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and unused medications at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and unused medications. By doing so, you will help protect the environment.
Composition of Eplerenona Combix
Opadry II. white OY-L-28900: lactose monohydrate, hypromellose (Type 2910), titanium dioxide (E171), macrogol 4000 (tablet coating).
Appearance of the product and contents of the packaging
50 mg tablet: white to off-white coated tablets, round, biconvex, marked “CG4” on one face of the tablet and smooth (unmarked) on the other face.
Eplerenona Combix 50 mg coated tablets are available in blister packs of 30 and 50 tablets.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder:
Combix, S.L.U.
C/ Badajoz 2, Edificio 2
28223 Pozuelo de Alarcon (Madrid)
Responsible manufacturer:
Laboratorios LICONSA S.A.
Avenida Miralcampo 7, Polígono Industrial Miralcampo
19200 Azuqueca de Henares, Guadalajara
Spain
Last review date of this leaflet: August 2012
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.